Cleared Traditional

K013263 - FRED HUTCHINSON CANCER RESEARCH CENTER ENZYME ANTI-SR PROTEIN ANTIBODY TEST

K013263 is an FDA 510(k) clearance for FRED HUTCHINSON CANCER RESEARCH CENTER ..., manufactured by Fred Hutchinson Cancer Research Center. The device is a Class 2 Immunology device with product code LKP cleared through the Traditional 510(k) pathway after a 301-day FDA review.

K013263 · Fred Hutchinson Cancer Research Center · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 2002
Decision
301d
Days
Class 2
Risk

K013263 is an FDA 510(k) clearance for the FRED HUTCHINSON CANCER RESEARCH CENTER ENZYME ANTI-SR PROTEIN ANTIBODY TEST. Classified as Anti-sm Antibody, Antigen And Control (product code LKP), Class II - Special Controls.

Submitted by Fred Hutchinson Cancer Research Center (Carlsbad, US). The FDA issued a Cleared decision on July 29, 2002 after a review of 301 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5100 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Immunology review framework, consistent with the majority of Class II 510(k) submissions.

FDA 510(k) Submission Details - K013263

510(k) Number K013263 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 01, 2001
Decision Date July 29, 2002
Days to Decision 301 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
196d slower than avg
Panel avg: 105d · This submission: 301d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LKP Device Classification - Class 2, Special Controls

Product Code LKP Anti-sm Antibody, Antigen And Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - LKP Anti-sm Antibody, Antigen And Control

All 27
Devices cleared under the same product code (LKP) and FDA review panel - the closest regulatory comparables to K013263.
THERATEST EL-ANA PROFILES
K051066 · Theratest Laboratories, Inc. · Oct 2005
VARELISA SM ANTIBODIES, MODEL 18296
K042629 · Sweden Diagnostics (Germany) GmbH · Dec 2004
LIQUICHEK ANTI-SM CONTROL, POSITIVE, CATALOG #115
K024219 · Bio-Rad · Jan 2003
RHIGENE MESACUP2 TEST- SM
K000755 · Rhigene, Inc. · May 2000
VARELISA SM ANTIBODIES
K000312 · Pharmacia & Upjohn Co. · Mar 2000
AUTOSTAT II ANTI-SM ELISA
K990625 · Cogent Diagnotics , Ltd. · Apr 1999
K013263 · FRED HUTCHINSON CANCER RESEARCH CENTER ENZYME ANTI-SR PROTEIN ANTIBODY TEST
Download PDF Fred Hutchinson Cance…